CYP cynata therapeutics limited

Stem Cell News, page-443

  1. 496 Posts.
    lightbulb Created with Sketch. 148
    Cynata steering clear of the FBS problem.

    Imagine using FBS and ignoring the issue...

    "Immune Response The most important clinical concern in using FBS lies in its potential to provoke adverse reactions from bovine xenoproteins or disease from viral or prion contamination following injection of FBS-grown MSCs (8). MSCs have been shown to incorporate FBS proteins, which may lead to an expression of antibodies post-injection (33).….

    When children with osteogenesis imperfecta were injected with BM-MSCs, it was found that one of the six patients experienced an immune response against their MSC injection (37). This patient had developed antibodies against FBS with a 150-fold increase in these antibodies after their second injection suggesting that multiple injections can exacerbate immune responses (37)."

    Last edited by Artephius: 09/01/23
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
-0.005(2.86%)
Mkt cap ! $39.54M
Open High Low Value Volume
17.5¢ 17.5¢ 17.0¢ $42.82K 247.5K

Buyers (Bids)

No. Vol. Price($)
4 141820 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 73088 2
View Market Depth
Last trade - 14.00pm 07/08/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.